Full Text
REGD. No. D. L.-33004/99
The Gazette of India
CG-DL-E-28032025-262059
EXTRAORDINARY
PART II-Section 3-Sub-section (ii)
PUBLISHED BY AUTHORITY
No. 1470]
NEW DELHI, THURSDAY, MARCH 27, 2025/CHAITRA 6, 1947
THE GAZETTE OF INDIA : EXTRAORDINARY
[PART II-SEC. 3(ii)]
MINISTRY OF CHEMICALS AND FERTILIZERS NOTIFICATION
(Department of Pharmaceuticals)
(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)
ORDER
New Delhi, the 27th March, 2025
S.O. 1488(E).—In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the
Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated 30th May, 2013, S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession
of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical
Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the
National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below
as ceiling prices exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulations
specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit
specified respectively in the corresponding entries in columns (3) and (4) thereof:
Table
Price Revision as per Annual Wholesale Price Index (WPI) @ 1.74028% increase
+-----+-----------------------+---------------------+-----------+---------------------------------+-------------------+
| SI. | Medicines | Dosage form | Unit | Ceiling price | Existing S.O. No. & Date|
| No. | | and Strength | | (wef 1.4.2025 | |
| | | | | with WPI @ | |
| | | | | 1.74028 %) (in | |
| | | | | Rs.) | |
+=====+=======================+=====================+===========+=================================+===================+
| (1) | (2) | (3) | (4) | (5) | 6(a) | 6(b) |
+-----+-----------------------+---------------------+-----------+---------------------------------+-----------+-----------+
| 1. | Acetyl Salicylic | Tablet 300 mg | 1 Tablet | 0.28 | 1549 (Ε) | 26-03-2024|
| | Acid | | | | | |
+-----+-----------------------+---------------------+-----------+---------------------------------+-----------+-----------+
| 2. | Calcium carbonate | Tablet 250 mg | 1 Tablet | 2.47 | 1549 (Ε) | 26-03-2024|
+-----+-----------------------+---------------------+-----------+---------------------------------+-----------+-----------+
| 3. | Condoms | | 1 Condom | 11.57 | 1549 (Ε) | 26-03-2024|
+-----+-----------------------+---------------------+-----------+---------------------------------+-----------+-----------+
| 4. | Dapsone | Tablet 50 mg | 1 Tablet | 0.30 | 1549 (Ε) | 26-03-2024|
+-----+-----------------------+---------------------+-----------+---------------------------------+-----------+-----------+
| 5. | Medroxy | Tablet 5 mg | 1 Tablet | 3.78 | 1549 (Ε) | 26-03-2024|
| | Progesterone | | | | | |
| | Acetate | | | | | |
+-----+-----------------------+---------------------+-----------+---------------------------------+-----------+-----------+
| 6. | Rifampicin | Tablet 450 mg | 1 Tablet | 5.62 | 1549 (Ε) | 26-03-2024|
+-----+-----------------------+---------------------+-----------+---------------------------------+-----------+-----------+
4
THE GAZETTE OF INDIA : EXTRAORDINARY
[PART II-SEC. 3(ii)]
Notes:—
(a) The ceiling prices are applicable with effect from 1.4.2025 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 1.74028% for the year 2024 over 2023).
(b) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled
formulations at a price higher than the ceiling price (plus Goods and Services Taxes as applicable) so fixed
and notified by the Government, shall revise the prices of all such formulations downward not exceeding the
ceiling price specified in column (5) in the above table plus Goods and Services Taxes as applicable, if any.
(c) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the
ceiling price notified vide S.O. No. & date as specified in column 6 (a)& 6 (b) in the above table (plus Goods
and Services Taxes as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis
of WPI @ 1.74028% for year 2024 over 2023 in accordance with paragraph 16(2) of DPCO, 2013.
(d) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(e) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the
concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised
maximum retail price (MRP), alongwith interest thereon from the date of overcharging.
(f) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of
Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State
Drug Controller and dealers.
(g) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(h) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer
shall apply for prior price approval of such new drug to the NPPA in Form-I as specified under Schedule-II
of the DPCO, 2013.
(i) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in
respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO,
2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled
formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import
of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the
intended date of discontinuation.
(j) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the DPCO, 2013 read
with Essential Commodities Act, 1955.
(k) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
[PN/263/131/2025/F F. No. 8(131)/2025/D.P./NPPA-Div.-II]
MAHAVEER SAINI, Deputy Director(Pricing)
Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054.